Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831310 | 1.00 | MAPK14 (0.53) | MAPK14PTK6EGFRTTBK1TTBK2 | |
| SCHEMBL23164306 | 0.94 | MAPK14 (0.54) | MAPK14PTK6EGFRTTBK1TTBK2 | |
| SCHEMBL29831171 | 0.93 | MAPK14 (0.53) | MAPK14PTK6EGFRTTBK1TTBK2 | |
| SCHEMBL23164316 | 0.93 | MAPK14 (0.53) | MAPK14PTK6EGFRTTBK1TTBK2 | |
| SCHEMBL29831299 | 0.92 | MAPK14 (0.54) | MAPK14PTK6EGFRAURKBDRD2 | |
| SCHEMBL23163745 | 0.92 | MAPK14 (0.54) | MAPK14PTK6EGFRDRD2DRD4 | |
| SCHEMBL29830990 | 0.91 | MAPK14 (0.58) | MAPK14PTK6DYRK1B | |
| SCHEMBL23164295 | 0.91 | MAPK14 (0.58) | MAPK14PTK6DYRK1B | |
| SCHEMBL23164292 | 0.91 | MAPK14 (0.56) | MAPK14EGFRTTBK1TTBK2AURKB | |
| SCHEMBL29831790 | 0.91 | MAPK14 (0.56) | MAPK14EGFRTTBK1TTBK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-07-08 | — | — | US | disclosed |
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FD (FR) | 2022-11-17 | — | — | US | disclosed |
| WO-2021064186-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | P2RX3, OPRL1, P2RX6 | MAPK14 1747/4885PTK6 1657/4885EGFR 4731/4885 |
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | P2RX3, P2RX6, P2RX4 | MAPK14 1641/4885PTK6 1464/4885EGFR 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.